108 related articles for article (PubMed ID: 19856473)
1. Application of an allele-specific PCR to clinical HIV genotyping samples detects additional K103N mutations in both therapy naïve and experienced patients.
Carr JM; Green T; Shaw D; Daly L; Hart W; Ratcliff R; Higgins G; Burrell CJ; Li P; Qiao M
J Med Virol; 2009 Dec; 81(12):1983-90. PubMed ID: 19856473
[TBL] [Abstract][Full Text] [Related]
2. Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy.
Palmer S; Boltz V; Maldarelli F; Kearney M; Halvas EK; Rock D; Falloon J; Davey RT; Dewar RL; Metcalf JA; Mellors JW; Coffin JM
AIDS; 2006 Mar; 20(5):701-10. PubMed ID: 16514300
[TBL] [Abstract][Full Text] [Related]
3. Detection of residual human immunodeficiency virus type 1 reverse transcriptase K103N minority species in plasma RNA and peripheral blood mononuclear cell DNA following discontinuation of non-nucleoside therapy.
Saladini F; Vicenti I; Razzolini F; Zazzi M
Clin Microbiol Infect; 2010 Jul; 16(7):848-51. PubMed ID: 19681953
[TBL] [Abstract][Full Text] [Related]
4. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients.
Metzner KJ; Giulieri SG; Knoepfel SA; Rauch P; Burgisser P; Yerly S; Günthard HF; Cavassini M
Clin Infect Dis; 2009 Jan; 48(2):239-47. PubMed ID: 19086910
[TBL] [Abstract][Full Text] [Related]
5. Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.
Marcelin AG; Descamps D; Tamalet C; Cottalorda J; Izopet J; Delaugerre C; Morand-Joubert L; Trabaud MA; Bettinger D; Rogez S; Ruffault A; Henquell C; Signori-Schmuck A; Bouvier-Alias M; Vallet S; Masquelier B; Flandre P; Calvez V;
Antivir Ther; 2012; 17(1):119-23. PubMed ID: 22267476
[TBL] [Abstract][Full Text] [Related]
6. Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption.
Darwich L; Esteve A; Ruiz L; Bellido R; Clotet B; Martinez-Picado J
Antivir Ther; 2008; 13(7):945-51. PubMed ID: 19043929
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
[TBL] [Abstract][Full Text] [Related]
8. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
Bannister WP; Ruiz L; Cozzi-Lepri A; Mocroft A; Kirk O; Staszewski S; Loveday C; Karlsson A; Monforte Ad; Clotet B; Lundgren JD;
AIDS; 2008 Jan; 22(3):367-76. PubMed ID: 18195563
[TBL] [Abstract][Full Text] [Related]
9. Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients.
Metzner KJ; Scherrer AU; von Wyl V; Böni J; Yerly S; Klimkait T; Aubert V; Furrer H; Hirsch HH; Vernazza PL; Cavassini M; Calmy A; Bernasconi E; Weber R; Günthard HF;
AIDS; 2014 Sep; 28(15):2231-9. PubMed ID: 25036184
[TBL] [Abstract][Full Text] [Related]
10. Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy.
Goodman DD; Zhou Y; Margot NA; McColl DJ; Zhong L; Borroto-Esoda K; Miller MD; Svarovskaia ES
AIDS; 2011 Jan; 25(3):325-33. PubMed ID: 21157296
[TBL] [Abstract][Full Text] [Related]
11. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of minor variants of HIV strains at reverse transcriptase position 103 in therapy-naïve patients and their impact on the virological failure.
Balduin M; Oette M; Däumer MP; Hoffmann D; Pfister HJ; Kaiser R
J Clin Virol; 2009 May; 45(1):34-8. PubMed ID: 19375978
[TBL] [Abstract][Full Text] [Related]
13. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of anti-HIV treatment and drug-resistance mutations in some parts of China].
Han XX; Zhang M; Cui WG; Liu BG; Wang Yn; Zhang ZN; Liu J; Geng WQ; Diao YY; Dai D; Jiang YJ; Shang H
Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(11):760-4. PubMed ID: 15949383
[TBL] [Abstract][Full Text] [Related]
15. Implementation of an Italian multicentric care network for early HIV infection diagnosis: 1999-2001 report.
Capiluppi B; Saracco A; Gianotti N; Mussini C; Butini L; Tomasoni L; De Gennaro M; Rizzolo L; Monolo G; Cargnel A; Moioli C; Arici C; Portelli V; Rizzardini G; Lazzarin A; Tambussi G
J Biol Regul Homeost Agents; 2002; 16(1):73-8. PubMed ID: 12003179
[TBL] [Abstract][Full Text] [Related]
16. Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients.
Halvas EK; Wiegand A; Boltz VF; Kearney M; Nissley D; Wantman M; Hammer SM; Palmer S; Vaida F; Coffin JM; Mellors JW
J Infect Dis; 2010 Mar; 201(5):672-80. PubMed ID: 20102272
[TBL] [Abstract][Full Text] [Related]
17. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy.
Peuchant O; Thiébaut R; Capdepont S; Lavignolle-Aurillac V; Neau D; Morlat P; Dabis F; Fleury H; Masquelier B;
AIDS; 2008 Jul; 22(12):1417-23. PubMed ID: 18614864
[TBL] [Abstract][Full Text] [Related]
18. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
[TBL] [Abstract][Full Text] [Related]
19. Dynamics of 103K/N and 184M/V HIV-1 drug resistant populations: relative comparison in plasma virus RNA versus CD45RO+T cell proviral DNA.
Jakobsen MR; Tolstrup M; Bertelsen L; Laursen A; Obel N; Ostergaard L; Mohey R
J Clin Virol; 2007 Jul; 39(3):215-21. PubMed ID: 17540617
[TBL] [Abstract][Full Text] [Related]
20. Resistance-associated mutations in HIV-1 among patients failing first-line antiretroviral therapy.
Saini S; Bhalla P; Gautam H; Baveja UK; Pasha ST; Dewan R
J Int Assoc Physicians AIDS Care (Chic); 2012; 11(3):203-9. PubMed ID: 21990611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
